
Opinion|Videos|May 3, 2024
Clinical Trials Evaluating Lenvatinib Plus Everolimus in Advanced Renal Cell Carcinoma
The panel discusses the lenvatinib plus everolimus regimen for patients with advanced renal cell carcinoma, highlighting clinical trial data on its efficacy and safety profile.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5









































